Humanigen Inc. (HGEN) Prices 8M Share Common Offering at $8.50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/31/2026
- Wall Street ends higher as Amazon soothes AI jitters
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- KBR names its Mission Technology Solutions spinoff Trinzic
- Wall Street ends sharply higher, lifted by soaring Microsoft
- SCYNEXIS (SCYX) Move Attributed to Morning Note from Brookline
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Humanigen Announces Pricing of Public Offering of Common Stock and Commencement of Trading on Nasdaq Under the Symbol “HGEN”
September 17, 2020 9:14 PM EDTBURLINGAME, CA / ACCESSWIRE / September 17, 2020 / Humanigen, Inc. ("Humanigen") (OTCQB: HGEND)(NASDAQ: HGEN), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm' with its lead drug candidate lenzilumab, announced today that it has priced its underwritten public offering of 8,000,000 shares of common stock at a public offering price of $8.50 per share, resulting in gross proceeds to Humanigen of approximately $68 million, before deducting underwriting discounts and commissions and offering expenses. The offering is expected to close on or about... More
